nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Electrocardiogram ST segment—Fluorouracil—colon cancer	0.0857	0.0881	CcSEcCtD
Regadenoson—Oral discomfort—Capecitabine—colon cancer	0.049	0.0503	CcSEcCtD
Regadenoson—Pain in jaw—Vincristine—colon cancer	0.0266	0.0273	CcSEcCtD
Regadenoson—Ischaemia—Irinotecan—colon cancer	0.0231	0.0238	CcSEcCtD
Regadenoson—Altered state of consciousness—Vincristine—colon cancer	0.0188	0.0193	CcSEcCtD
Regadenoson—Pain in jaw—Capecitabine—colon cancer	0.0173	0.0178	CcSEcCtD
Regadenoson—Bronchial hyperreactivity—Methotrexate—colon cancer	0.0161	0.0165	CcSEcCtD
Regadenoson—Chronic obstructive pulmonary disease—Methotrexate—colon cancer	0.0147	0.0151	CcSEcCtD
Regadenoson—Respiratory distress—Vincristine—colon cancer	0.0136	0.014	CcSEcCtD
Regadenoson—Altered state of consciousness—Capecitabine—colon cancer	0.0122	0.0126	CcSEcCtD
Regadenoson—Adenosine triphosphate—AKT1—colon cancer	0.0121	0.463	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—colon cancer	0.012	0.456	CrCbGaD
Regadenoson—Peripheral coldness—Capecitabine—colon cancer	0.0119	0.0122	CcSEcCtD
Regadenoson—Transient ischaemic attack—Capecitabine—colon cancer	0.0112	0.0115	CcSEcCtD
Regadenoson—Myocardial ischaemia—Irinotecan—colon cancer	0.0105	0.0108	CcSEcCtD
Regadenoson—Myocardial ischaemia—Fluorouracil—colon cancer	0.0101	0.0103	CcSEcCtD
Regadenoson—Vasodilation—Irinotecan—colon cancer	0.00961	0.00986	CcSEcCtD
Regadenoson—Vasodilation procedure—Irinotecan—colon cancer	0.00961	0.00986	CcSEcCtD
Regadenoson—Respiratory distress—Capecitabine—colon cancer	0.00889	0.00913	CcSEcCtD
Regadenoson—Musculoskeletal pain—Vincristine—colon cancer	0.00877	0.00901	CcSEcCtD
Regadenoson—Myocardial ischaemia—Capecitabine—colon cancer	0.00703	0.00722	CcSEcCtD
Regadenoson—Injection site pain—Capecitabine—colon cancer	0.00692	0.00711	CcSEcCtD
Regadenoson—Extrasystoles—Capecitabine—colon cancer	0.00671	0.00689	CcSEcCtD
Regadenoson—Renal impairment—Irinotecan—colon cancer	0.00644	0.00661	CcSEcCtD
Regadenoson—Chest discomfort—Capecitabine—colon cancer	0.00638	0.00656	CcSEcCtD
Regadenoson—Pain in extremity—Vincristine—colon cancer	0.00629	0.00646	CcSEcCtD
Regadenoson—Cerebrovascular accident—Irinotecan—colon cancer	0.00625	0.00642	CcSEcCtD
Regadenoson—Cardiac arrest—Vincristine—colon cancer	0.00598	0.00614	CcSEcCtD
Regadenoson—Cardiac arrest—Irinotecan—colon cancer	0.00583	0.00598	CcSEcCtD
Regadenoson—Cardiac arrest—Fluorouracil—colon cancer	0.00558	0.00573	CcSEcCtD
Regadenoson—Depressed level of consciousness—Capecitabine—colon cancer	0.00545	0.0056	CcSEcCtD
Regadenoson—Abdominal distension—Irinotecan—colon cancer	0.00533	0.00547	CcSEcCtD
Regadenoson—Angina pectoris—Irinotecan—colon cancer	0.00516	0.0053	CcSEcCtD
Regadenoson—Angina pectoris—Fluorouracil—colon cancer	0.00494	0.00507	CcSEcCtD
Regadenoson—Acute coronary syndrome—Vincristine—colon cancer	0.00478	0.00491	CcSEcCtD
Regadenoson—Myocardial infarction—Vincristine—colon cancer	0.00475	0.00488	CcSEcCtD
Regadenoson—Acute coronary syndrome—Irinotecan—colon cancer	0.00465	0.00478	CcSEcCtD
Regadenoson—Renal failure—Irinotecan—colon cancer	0.00464	0.00477	CcSEcCtD
Regadenoson—Myocardial infarction—Irinotecan—colon cancer	0.00463	0.00475	CcSEcCtD
Regadenoson—Eye pain—Capecitabine—colon cancer	0.00454	0.00466	CcSEcCtD
Regadenoson—Acute coronary syndrome—Fluorouracil—colon cancer	0.00446	0.00458	CcSEcCtD
Regadenoson—Myocardial infarction—Fluorouracil—colon cancer	0.00443	0.00455	CcSEcCtD
Regadenoson—Hypoaesthesia—Vincristine—colon cancer	0.00433	0.00445	CcSEcCtD
Regadenoson—Atrial fibrillation—Capecitabine—colon cancer	0.00433	0.00444	CcSEcCtD
Regadenoson—Bradycardia—Irinotecan—colon cancer	0.00431	0.00443	CcSEcCtD
Regadenoson—Renal impairment—Capecitabine—colon cancer	0.00431	0.00442	CcSEcCtD
Regadenoson—Connective tissue disorder—Vincristine—colon cancer	0.00428	0.00439	CcSEcCtD
Regadenoson—Cerebrovascular accident—Capecitabine—colon cancer	0.00418	0.0043	CcSEcCtD
Regadenoson—Connective tissue disorder—Irinotecan—colon cancer	0.00416	0.00428	CcSEcCtD
Regadenoson—Pain in extremity—Capecitabine—colon cancer	0.0041	0.00421	CcSEcCtD
Regadenoson—Depressed level of consciousness—Methotrexate—colon cancer	0.00406	0.00417	CcSEcCtD
Regadenoson—Cardiac disorder—Vincristine—colon cancer	0.00404	0.00415	CcSEcCtD
Regadenoson—Hypoaesthesia—Fluorouracil—colon cancer	0.00404	0.00415	CcSEcCtD
Regadenoson—Angiopathy—Vincristine—colon cancer	0.00395	0.00405	CcSEcCtD
Regadenoson—Flushing—Irinotecan—colon cancer	0.00393	0.00404	CcSEcCtD
Regadenoson—Cardiac disorder—Irinotecan—colon cancer	0.00393	0.00404	CcSEcCtD
Regadenoson—Mediastinal disorder—Vincristine—colon cancer	0.00392	0.00403	CcSEcCtD
Regadenoson—Cardiac arrest—Capecitabine—colon cancer	0.0039	0.004	CcSEcCtD
Regadenoson—Angiopathy—Irinotecan—colon cancer	0.00385	0.00395	CcSEcCtD
Regadenoson—Immune system disorder—Irinotecan—colon cancer	0.00383	0.00393	CcSEcCtD
Regadenoson—Mediastinal disorder—Irinotecan—colon cancer	0.00382	0.00392	CcSEcCtD
Regadenoson—Mental disorder—Vincristine—colon cancer	0.00381	0.00392	CcSEcCtD
Regadenoson—Abdominal distension—Capecitabine—colon cancer	0.00357	0.00366	CcSEcCtD
Regadenoson—Asthma—Capecitabine—colon cancer	0.00354	0.00364	CcSEcCtD
Regadenoson—Erythema—Fluorouracil—colon cancer	0.00353	0.00363	CcSEcCtD
Regadenoson—Bronchospasm—Capecitabine—colon cancer	0.00349	0.00358	CcSEcCtD
Regadenoson—Angina pectoris—Capecitabine—colon cancer	0.00345	0.00355	CcSEcCtD
Regadenoson—Ill-defined disorder—Irinotecan—colon cancer	0.00342	0.00352	CcSEcCtD
Regadenoson—Abdominal discomfort—Capecitabine—colon cancer	0.0034	0.00349	CcSEcCtD
Regadenoson—Vision blurred—Fluorouracil—colon cancer	0.00333	0.00342	CcSEcCtD
Regadenoson—Malaise—Irinotecan—colon cancer	0.00333	0.00342	CcSEcCtD
Regadenoson—Syncope—Irinotecan—colon cancer	0.00331	0.0034	CcSEcCtD
Regadenoson—Convulsion—Vincristine—colon cancer	0.00328	0.00337	CcSEcCtD
Regadenoson—Hypertension—Vincristine—colon cancer	0.00327	0.00336	CcSEcCtD
Regadenoson—Loss of consciousness—Irinotecan—colon cancer	0.00324	0.00333	CcSEcCtD
Regadenoson—Myalgia—Vincristine—colon cancer	0.00323	0.00331	CcSEcCtD
Regadenoson—Cough—Irinotecan—colon cancer	0.00322	0.00331	CcSEcCtD
Regadenoson—Hypertension—Irinotecan—colon cancer	0.00319	0.00327	CcSEcCtD
Regadenoson—Acute coronary syndrome—Capecitabine—colon cancer	0.00311	0.0032	CcSEcCtD
Regadenoson—Cerebrovascular accident—Methotrexate—colon cancer	0.00311	0.0032	CcSEcCtD
Regadenoson—Renal failure—Capecitabine—colon cancer	0.00311	0.00319	CcSEcCtD
Regadenoson—Discomfort—Irinotecan—colon cancer	0.0031	0.00319	CcSEcCtD
Regadenoson—Myocardial infarction—Capecitabine—colon cancer	0.0031	0.00318	CcSEcCtD
Regadenoson—Anaphylactic shock—Vincristine—colon cancer	0.00309	0.00318	CcSEcCtD
Regadenoson—Convulsion—Fluorouracil—colon cancer	0.00306	0.00314	CcSEcCtD
Regadenoson—Nervous system disorder—Vincristine—colon cancer	0.00303	0.00311	CcSEcCtD
Regadenoson—Anaphylactic shock—Irinotecan—colon cancer	0.00301	0.00309	CcSEcCtD
Regadenoson—Myalgia—Fluorouracil—colon cancer	0.00301	0.00309	CcSEcCtD
Regadenoson—Chest pain—Fluorouracil—colon cancer	0.00301	0.00309	CcSEcCtD
Regadenoson—Hyperhidrosis—Vincristine—colon cancer	0.00299	0.00307	CcSEcCtD
Regadenoson—Discomfort—Fluorouracil—colon cancer	0.00297	0.00305	CcSEcCtD
Regadenoson—Shock—Irinotecan—colon cancer	0.00296	0.00304	CcSEcCtD
Regadenoson—Nervous system disorder—Irinotecan—colon cancer	0.00295	0.00303	CcSEcCtD
Regadenoson—Hyperhidrosis—Irinotecan—colon cancer	0.00291	0.00299	CcSEcCtD
Regadenoson—Hypotension—Vincristine—colon cancer	0.00289	0.00297	CcSEcCtD
Regadenoson—Bradycardia—Capecitabine—colon cancer	0.00289	0.00297	CcSEcCtD
Regadenoson—Anaphylactic shock—Fluorouracil—colon cancer	0.00288	0.00296	CcSEcCtD
Regadenoson—Nervous system disorder—Fluorouracil—colon cancer	0.00283	0.0029	CcSEcCtD
Regadenoson—Hypoaesthesia—Capecitabine—colon cancer	0.00282	0.0029	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vincristine—colon cancer	0.00282	0.00289	CcSEcCtD
Regadenoson—Tachycardia—Fluorouracil—colon cancer	0.00281	0.00289	CcSEcCtD
Regadenoson—Hypotension—Irinotecan—colon cancer	0.00281	0.00289	CcSEcCtD
Regadenoson—Insomnia—Vincristine—colon cancer	0.0028	0.00287	CcSEcCtD
Regadenoson—Connective tissue disorder—Capecitabine—colon cancer	0.00279	0.00286	CcSEcCtD
Regadenoson—Paraesthesia—Vincristine—colon cancer	0.00278	0.00285	CcSEcCtD
Regadenoson—Insomnia—Irinotecan—colon cancer	0.00272	0.0028	CcSEcCtD
Regadenoson—Paraesthesia—Irinotecan—colon cancer	0.0027	0.00278	CcSEcCtD
Regadenoson—Hypotension—Fluorouracil—colon cancer	0.00269	0.00277	CcSEcCtD
Regadenoson—Dyspnoea—Irinotecan—colon cancer	0.00268	0.00276	CcSEcCtD
Regadenoson—Somnolence—Irinotecan—colon cancer	0.00268	0.00275	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vincristine—colon cancer	0.00267	0.00274	CcSEcCtD
Regadenoson—Eye disorder—Capecitabine—colon cancer	0.00265	0.00272	CcSEcCtD
Regadenoson—Tinnitus—Capecitabine—colon cancer	0.00264	0.00272	CcSEcCtD
Regadenoson—Pain—Vincristine—colon cancer	0.00264	0.00272	CcSEcCtD
Regadenoson—Asthma—Methotrexate—colon cancer	0.00264	0.00271	CcSEcCtD
Regadenoson—Cardiac disorder—Capecitabine—colon cancer	0.00263	0.0027	CcSEcCtD
Regadenoson—Flushing—Capecitabine—colon cancer	0.00263	0.0027	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00263	0.0027	CcSEcCtD
Regadenoson—Insomnia—Fluorouracil—colon cancer	0.00261	0.00268	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Irinotecan—colon cancer	0.0026	0.00267	CcSEcCtD
Regadenoson—Paraesthesia—Fluorouracil—colon cancer	0.00259	0.00266	CcSEcCtD
Regadenoson—Pain—Irinotecan—colon cancer	0.00257	0.00264	CcSEcCtD
Regadenoson—Angiopathy—Capecitabine—colon cancer	0.00257	0.00264	CcSEcCtD
Regadenoson—Dyspnoea—Fluorouracil—colon cancer	0.00257	0.00264	CcSEcCtD
Regadenoson—Somnolence—Fluorouracil—colon cancer	0.00256	0.00263	CcSEcCtD
Regadenoson—Immune system disorder—Capecitabine—colon cancer	0.00256	0.00263	CcSEcCtD
Regadenoson—Mediastinal disorder—Capecitabine—colon cancer	0.00256	0.00263	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—colon cancer	0.00253	0.0026	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vincristine—colon cancer	0.00253	0.0026	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00249	0.00256	CcSEcCtD
Regadenoson—Mental disorder—Capecitabine—colon cancer	0.00249	0.00255	CcSEcCtD
Regadenoson—Feeling abnormal—Irinotecan—colon cancer	0.00248	0.00255	CcSEcCtD
Regadenoson—Erythema—Capecitabine—colon cancer	0.00247	0.00254	CcSEcCtD
Regadenoson—Pain—Fluorouracil—colon cancer	0.00247	0.00253	CcSEcCtD
Regadenoson—Gastrointestinal pain—Irinotecan—colon cancer	0.00246	0.00253	CcSEcCtD
Regadenoson—Abdominal pain—Vincristine—colon cancer	0.00244	0.00251	CcSEcCtD
Regadenoson—Dysgeusia—Capecitabine—colon cancer	0.00242	0.00248	CcSEcCtD
Regadenoson—Abdominal pain—Irinotecan—colon cancer	0.00238	0.00244	CcSEcCtD
Regadenoson—Feeling abnormal—Fluorouracil—colon cancer	0.00238	0.00244	CcSEcCtD
Regadenoson—Vision blurred—Capecitabine—colon cancer	0.00233	0.00239	CcSEcCtD
Regadenoson—Tremor—Capecitabine—colon cancer	0.00231	0.00238	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—colon cancer	0.00231	0.00237	CcSEcCtD
Regadenoson—Ill-defined disorder—Capecitabine—colon cancer	0.00229	0.00235	CcSEcCtD
Regadenoson—Urticaria—Fluorouracil—colon cancer	0.00229	0.00235	CcSEcCtD
Regadenoson—Hypersensitivity—Vincristine—colon cancer	0.00228	0.00234	CcSEcCtD
Regadenoson—Malaise—Capecitabine—colon cancer	0.00223	0.00229	CcSEcCtD
Regadenoson—Hypersensitivity—Irinotecan—colon cancer	0.00222	0.00228	CcSEcCtD
Regadenoson—Asthenia—Vincristine—colon cancer	0.00222	0.00228	CcSEcCtD
Regadenoson—Syncope—Capecitabine—colon cancer	0.00221	0.00227	CcSEcCtD
Regadenoson—Palpitations—Capecitabine—colon cancer	0.00218	0.00224	CcSEcCtD
Regadenoson—Loss of consciousness—Capecitabine—colon cancer	0.00217	0.00223	CcSEcCtD
Regadenoson—Asthenia—Irinotecan—colon cancer	0.00216	0.00222	CcSEcCtD
Regadenoson—Cough—Capecitabine—colon cancer	0.00215	0.00221	CcSEcCtD
Regadenoson—Hypertension—Capecitabine—colon cancer	0.00213	0.00219	CcSEcCtD
Regadenoson—Hypersensitivity—Fluorouracil—colon cancer	0.00212	0.00218	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCB1—colon cancer	0.00212	0.0808	CrCbGaD
Regadenoson—Diarrhoea—Vincristine—colon cancer	0.00212	0.00217	CcSEcCtD
Regadenoson—Chest pain—Capecitabine—colon cancer	0.0021	0.00216	CcSEcCtD
Regadenoson—Arthralgia—Capecitabine—colon cancer	0.0021	0.00216	CcSEcCtD
Regadenoson—Myalgia—Capecitabine—colon cancer	0.0021	0.00216	CcSEcCtD
Regadenoson—Anxiety—Capecitabine—colon cancer	0.0021	0.00215	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00209	0.00214	CcSEcCtD
Regadenoson—Discomfort—Capecitabine—colon cancer	0.00208	0.00213	CcSEcCtD
Regadenoson—Diarrhoea—Irinotecan—colon cancer	0.00206	0.00212	CcSEcCtD
Regadenoson—Dizziness—Vincristine—colon cancer	0.00204	0.0021	CcSEcCtD
Regadenoson—Dizziness—Irinotecan—colon cancer	0.00199	0.00204	CcSEcCtD
Regadenoson—Shock—Capecitabine—colon cancer	0.00198	0.00204	CcSEcCtD
Regadenoson—Nervous system disorder—Capecitabine—colon cancer	0.00198	0.00203	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—colon cancer	0.00197	0.00203	CcSEcCtD
Regadenoson—Diarrhoea—Fluorouracil—colon cancer	0.00197	0.00203	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—colon cancer	0.00197	0.00202	CcSEcCtD
Regadenoson—Tachycardia—Capecitabine—colon cancer	0.00197	0.00202	CcSEcCtD
Regadenoson—Vomiting—Vincristine—colon cancer	0.00197	0.00202	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—colon cancer	0.00196	0.00201	CcSEcCtD
Regadenoson—Skin disorder—Capecitabine—colon cancer	0.00196	0.00201	CcSEcCtD
Regadenoson—Rash—Vincristine—colon cancer	0.00195	0.002	CcSEcCtD
Regadenoson—Hyperhidrosis—Capecitabine—colon cancer	0.00195	0.002	CcSEcCtD
Regadenoson—Dermatitis—Vincristine—colon cancer	0.00195	0.002	CcSEcCtD
Regadenoson—Headache—Vincristine—colon cancer	0.00194	0.00199	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—colon cancer	0.00192	0.00197	CcSEcCtD
Regadenoson—Vomiting—Irinotecan—colon cancer	0.00191	0.00197	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—colon cancer	0.00191	0.00196	CcSEcCtD
Regadenoson—Dizziness—Fluorouracil—colon cancer	0.00191	0.00196	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—colon cancer	0.0019	0.00195	CcSEcCtD
Regadenoson—Rash—Irinotecan—colon cancer	0.0019	0.00195	CcSEcCtD
Regadenoson—Dermatitis—Irinotecan—colon cancer	0.0019	0.00195	CcSEcCtD
Regadenoson—Headache—Irinotecan—colon cancer	0.00189	0.00194	CcSEcCtD
Regadenoson—Hypotension—Capecitabine—colon cancer	0.00188	0.00193	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—colon cancer	0.00185	0.0019	CcSEcCtD
Regadenoson—Erythema—Methotrexate—colon cancer	0.00184	0.00189	CcSEcCtD
Regadenoson—Nausea—Vincristine—colon cancer	0.00184	0.00189	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00184	0.00189	CcSEcCtD
Regadenoson—Vomiting—Fluorouracil—colon cancer	0.00183	0.00188	CcSEcCtD
Regadenoson—Insomnia—Capecitabine—colon cancer	0.00182	0.00187	CcSEcCtD
Regadenoson—Rash—Fluorouracil—colon cancer	0.00182	0.00187	CcSEcCtD
Regadenoson—Dermatitis—Fluorouracil—colon cancer	0.00182	0.00187	CcSEcCtD
Regadenoson—Paraesthesia—Capecitabine—colon cancer	0.00181	0.00186	CcSEcCtD
Regadenoson—Headache—Fluorouracil—colon cancer	0.00181	0.00186	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—colon cancer	0.0018	0.00185	CcSEcCtD
Regadenoson—Dyspnoea—Capecitabine—colon cancer	0.0018	0.00185	CcSEcCtD
Regadenoson—Nausea—Irinotecan—colon cancer	0.00179	0.00184	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Capecitabine—colon cancer	0.00174	0.00179	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—colon cancer	0.00173	0.00178	CcSEcCtD
Regadenoson—Pain—Capecitabine—colon cancer	0.00172	0.00177	CcSEcCtD
Regadenoson—Nausea—Fluorouracil—colon cancer	0.00171	0.00176	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—colon cancer	0.00171	0.00175	CcSEcCtD
Regadenoson—Feeling abnormal—Capecitabine—colon cancer	0.00166	0.00171	CcSEcCtD
Regadenoson—Malaise—Methotrexate—colon cancer	0.00166	0.0017	CcSEcCtD
Regadenoson—Gastrointestinal pain—Capecitabine—colon cancer	0.00165	0.00169	CcSEcCtD
Regadenoson—Cough—Methotrexate—colon cancer	0.0016	0.00165	CcSEcCtD
Regadenoson—Urticaria—Capecitabine—colon cancer	0.0016	0.00164	CcSEcCtD
Regadenoson—Abdominal pain—Capecitabine—colon cancer	0.00159	0.00164	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—colon cancer	0.00159	0.00164	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—colon cancer	0.00156	0.00161	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—colon cancer	0.00156	0.00161	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—colon cancer	0.00156	0.00161	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00155	0.0016	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—colon cancer	0.00155	0.00159	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—colon cancer	0.0015	0.00154	CcSEcCtD
Regadenoson—Hypersensitivity—Capecitabine—colon cancer	0.00148	0.00152	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—colon cancer	0.00147	0.00151	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—colon cancer	0.00146	0.0015	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—colon cancer	0.00145	0.00149	CcSEcCtD
Regadenoson—Asthenia—Capecitabine—colon cancer	0.00145	0.00148	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—colon cancer	0.0014	0.00144	CcSEcCtD
Regadenoson—Diarrhoea—Capecitabine—colon cancer	0.00138	0.00142	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00137	0.0014	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—colon cancer	0.00136	0.00139	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—colon cancer	0.00135	0.00138	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—colon cancer	0.00134	0.00137	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—colon cancer	0.00133	0.00137	CcSEcCtD
Regadenoson—Dizziness—Capecitabine—colon cancer	0.00133	0.00137	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—colon cancer	0.0013	0.00133	CcSEcCtD
Regadenoson—Pain—Methotrexate—colon cancer	0.00128	0.00132	CcSEcCtD
Regadenoson—Vomiting—Capecitabine—colon cancer	0.00128	0.00132	CcSEcCtD
Regadenoson—Rash—Capecitabine—colon cancer	0.00127	0.0013	CcSEcCtD
Regadenoson—Dermatitis—Capecitabine—colon cancer	0.00127	0.0013	CcSEcCtD
Regadenoson—Headache—Capecitabine—colon cancer	0.00126	0.0013	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—colon cancer	0.00124	0.00127	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—colon cancer	0.00123	0.00126	CcSEcCtD
Regadenoson—Nausea—Capecitabine—colon cancer	0.0012	0.00123	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—colon cancer	0.00119	0.00122	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—colon cancer	0.00119	0.00122	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—colon cancer	0.00111	0.00114	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—colon cancer	0.00108	0.00111	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—colon cancer	0.00103	0.00105	CcSEcCtD
Regadenoson—Dizziness—Methotrexate—colon cancer	0.000992	0.00102	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—colon cancer	0.000954	0.00098	CcSEcCtD
Regadenoson—Rash—Methotrexate—colon cancer	0.000946	0.000971	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—colon cancer	0.000945	0.000971	CcSEcCtD
Regadenoson—Headache—Methotrexate—colon cancer	0.00094	0.000965	CcSEcCtD
Regadenoson—Nausea—Methotrexate—colon cancer	0.000891	0.000915	CcSEcCtD
